A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion

Cancer

Volumn 118, Issue 24, 2012, Pages 6136-6143

  Beasley, Georgia M ^a   Sharma, Ketan ^a   Wong, Joyce ^b   Miller, Mike ^a   Turley, Ryan S ^a   Lidsky, Michael ^a   Masoud, Melanie ^a   Dewhirst, Mark W ^a   Mosca, Paul J ^a   Zager, Jonathan S ^b   Tyler, Douglas S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

in transit disease; limb infusion; melanoma; melphalan; tumor hypoxia

Indexed keywords

MELPHALAN;

ADULT; AGED; ARM; ARTICLE; BLOOD PH; CANCER CHEMOTHERAPY; CLINICAL EXAMINATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE SEVERITY; DRUG ADMINISTRATION ROUTE; DRUG SAFETY; FEMALE; HUMAN; INFUSION; INTERMETHOD COMPARISON; ISOLATED LIMB INFUSION; LEG; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MERKEL CELL TUMOR; MINIMALLY INVASIVE PROCEDURE; MULTICENTER STUDY; PRIORITY JOURNAL; SARCOMA; SIDE EFFECT; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA, MERKEL CELL; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOWER EXTREMITY; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SARCOMA; SURVIVAL RATE; UPPER EXTREMITY; YOUNG ADULT;

EID: 84870700338     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27676     Document Type: Article

References (15)

1. Beasley GM, Petersen RP, Yoo YS,. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008; 15: 2195-2205.
2. Brady MS, Brown K, Patel A, et al. Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial. Melanoma Res. 2009; 19: 106-111.
3. Kroon HM, Moncrieff M, Kam PCA, et al. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol. 2008; 15: 3003-3013.
4. Beasley GM, Caudle A, Petersen RP, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg. 2009; 208: 706-715; discussion 715-717.
5. Moncrieff M, Kroon H, Kam PCA,. Isolated limb infusion for advanced soft tissue sarcoma of the extremity. Ann Surg Oncol. 2008; 15: 2749-2756.
6. Raymond AK, Beasley GM, Broadwater G, et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg. 2011; 213: 306-316.
7. Vyas A, Avritscher R, Ensor J, Ross M, Wallace MJ,. Isolated limb infusion with cytotoxic agents: a simplified approach for venous access. Cancer. 2010; 116: 459-464.
8. McMahon N, Cheng TY, Beasley GM, et al. Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol. 2009; 16: 953-961.
9. Cheng TY, Gruubs E, Abduke-Wahab O, et al. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. Am J Surg. 2003; 186: 460-467.
10. Ehrsson H, Eksborg S, Lindfors A,. Quantitative determination of melphalan in plasma by liquid chromatography after derivatization with N-acetylcysteine. J Chromatogr. 1986; 380: 222-229.
11. Beasley GM, Riboh J, Augustine CK, et al. Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol. 2011; 29: 1210-1215.
12. McMahon N, Beasley G, Sanders G, et al. A phase I study of systemic sorafenib in combination with isolated limb infusion with melphalan (ILI-M) in patients (pts) with locally advanced in-transit melanoma [abstract]. J Clin Oncol. 2009; 27 (15S). Abstract 9065.
13. Skarsgard LD, Skwarchuk MW, Vinczan A, et al. The cytotoxicity of melphalan and its relationship to pH, hypoxia, and drug uptake. Anticancer Res. 1995; 15: 219-223.
14. Thompson JF, Anisimov YG, Smithers BM, et al. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Br J Cancer. 2001; 85: 157-165.
15. Prescott DM, Charles HC, Poulson JM, et al. The relationship between intracellular and extracellular pH in the spontaneous canine tumors. Clin Cancer Res. 2000; 6: 2501-2505.